Results 1 to 10 of about 209,011 (190)

HIV protease inhibitors: a review of molecular selectivity and toxicity [PDF]

open access: yesHIV/AIDS: Research and Palliative Care, 2015
Zhengtong Lv,* Yuan Chu,* Yong Wang Department of Immunology, School of Basic Medical Science, Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China *Both authors contributed equally to this work ...
Lv Z, Chu Y, Wang Y
doaj   +3 more sources

Molecular dynamics simulation of docking structures of SARS-CoV-2 main protease and HIV protease inhibitors [PDF]

open access: yesJournal of Molecular Structure, 2021
Highlights • We consider possible repurposed-drugs candidates against SARS-CoV-2.• 10 different HIV protease inhibitors were investigated.• In silico simulations were used to study protease inhibitors for SARS-CoV-2.
Wesley B Cardoso   +1 more
exaly   +3 more sources

Molecular Mechanisms of HIV Protease Inhibitors Against HPV-Associated Cervical Cancer: Restoration of TP53 Tumour Suppressor Activities [PDF]

open access: yesFrontiers in Molecular Biosciences, 2022
Cervical cancer is a Human Papilloma virus-related disease, which is on the rise in a number of countries, globally. Two essential oncogenes, E6 and E7, drive cell transformation and cancer development.
Lilian Makgoo   +2 more
doaj   +2 more sources

Susceptibility of HPV-18 Cancer Cells to HIV Protease Inhibitors [PDF]

open access: yesViruses
Cervical cancer cases continue to rise despite all the advanced screening and preventative measures put in place, which include human papillomavirus (HPV) vaccination.
Lilian Makgoo   +2 more
doaj   +2 more sources

Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design [PDF]

open access: yesMolecules, 2021
SARS-CoV-2 is highly homologous to SARS-CoV. To date, the main protease (Mpro) of SARS-CoV-2 is regarded as an important drug target for the treatment of Coronavirus Disease 2019 (COVID-19). Some experiments confirmed that several HIV protease inhibitors
Wei Yu   +14 more
doaj   +2 more sources

HIV protease inhibitors restore amphotericin B activity against Candida. [PDF]

open access: yesPLoS ONE
Candida auris is an invasive fungal pathogen, representing a global public health threat. It is characterized by high mortality rates among infected individuals, significant antifungal resistance, and a remarkable ability to persist in healthcare ...
Yehia Elgammal   +2 more
doaj   +2 more sources

Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System

open access: yesViruses, 2015
Retroviral protease inhibitors (PIs) are fundamental pillars in the treatment of HIV infection and acquired immunodeficiency syndrome (AIDS). Currently used PIs are designed against HIV-1, and their effect on HIV-2 is understudied.
Mohamed Mahdi   +3 more
doaj   +3 more sources

Current and Novel Inhibitors of HIV Protease

open access: yesViruses, 2009
The design, development and clinical success of HIV protease inhibitors represent one of the most remarkable achievements of molecular medicine. This review describes all nine currently available FDA-approved protease inhibitors, discusses their ...
Jan Konvalinka   +3 more
doaj   +3 more sources

HIV Protease: Historical Perspective and Current Research

open access: yesViruses, 2021
The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by ...
Irene T. Weber   +2 more
doaj   +1 more source

Drug Reprofiling to Identify Potential HIV-1 Protease Inhibitors

open access: yesMolecules, 2023
The use of protease inhibitors in human immunodeficiency virus type 1 (HIV-1) treatment is limited by adverse effects, including metabolic complications. To address these challenges, efforts are underway in the pursuit of more potent and less toxic HIV-1
Sunday N. Okafor   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy